Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers events reported on April 3, 2013, and April 7, 2013. The report details significant changes in executive leadership within the company's research and scientific divisions.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure: Elliott Sigal notified the company on April 3, 2013, of his retirement as Executive Vice President and Chief Scientific Officer and as a member of the Board of Directors, effective June 30, 2013.
- Appointment: On April 7, 2013, the company announced the promotion of Francis Cuss from Senior Vice President, Research, to Executive Vice President and Chief Scientific Officer, effective July 1, 2013.
- Background: Dr. Cuss joined the company in 2003 and has held various research leadership roles since 2006.
Compensation and Management Commentary
Effective July 1, 2013, Dr. Cuss's compensation package includes:
- Annual base salary of $875,000.
- Annual discretionary incentive payout with a target bonus opportunity of 100% of base salary.
- A long-term performance award valued at $500,000, structured as Restricted Stock Units with five-year vesting under the 2012 Stock Award and Incentive Plan.
- Participation in the standard annual long-term incentive award program.
- Change-in-control and severance benefits consistent with Named Executive Officers.
The filing states there are no related party transactions between the company and Dr. Cuss, and no arrangements with other persons influenced his selection.
Investor Verification Checklist
- Verify the exact effective dates for Elliott Sigal's retirement (June 30, 2013) and Francis Cuss's promotion (July 1, 2013).
- Confirm the vesting schedule and terms of the $500,000 long-term performance award for Dr. Cuss.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.